COVID-19 outcomes in haematopoietic cell transplant recipients: A systematic review and meta-analysis [0.03%]
造血干细胞移植受者的新冠肺炎转归：系统评价和Meta分析
Yeong Jer Lim,Umair Khan,Indrani Karpha et al.
Yeong Jer Lim et al.
Up-to-date information on coronavirus disease 2019 (COVID-19) outcomes and risk factors in haematopoietic cell transplantation (HCT) recipients is required to inform on decisions about cancer treatment and COVID-19 mitigation strategies. We...
Anjelica Cromartie,Meghan Prin
Anjelica Cromartie
Editorial
EJHaem. 2022 May 23;3(3):582-583. DOI:10.1002/jha2.430 2022
Sickle cell disease patients with COVID-19 in Guadeloupe: Surprisingly favorable outcomes [0.03%]
瓜德罗普镰状细胞疾病患者的新冠结局良好令人大跌眼镜
Emmanuelle Bernit,Marc Romana,Scylia Alexis-Fardini et al.
Emmanuelle Bernit et al.
We investigate risk factors for hospitalization and difference between sickle cell syndromes in a cohort of COVID-19 sickle cell disease (SCD) adult patients managed in the Reference Center of Guadeloupe. We retrospectively collected data o...
Use of daratumumab in high risk multiple myeloma: A meta-analysis [0.03%]
达拉莫单抗治疗高危多发性骨髓瘤的疗效和安全性：系统评价和 Meta 分析
Vikram Premkumar,Samuel Pan,Suzanne Lentzsch et al.
Vikram Premkumar et al.
Daratumumab is approved for use in newly diagnosed and relapsed/refractory multiple myeloma (MM), however the patients most likely to benefit from its addition to standard anti-myeloma therapy is unclear. This meta-analysis included 2340 ne...
Bone marrow mesenchymal stem cells as a possible ruxolitinib reservoir in the bone marrow niche [0.03%]
骨髓间充质干细胞可能是骨髓龛中的鲁索利替尼储库
Luigi Marino,Bruno Charlier,Valentina Giudice et al.
Luigi Marino et al.
Clinical features of children with polycythemia vera, essential thrombocythemia, and primary myelofibrosis in Japan: A retrospective nationwide survey [0.03%]
日本儿童真性红细胞增多症、原发性血小板增多症和原发性骨髓纤维化的临床特征：一项全国性的回顾性调查
Hisashi Ishida,Yuji Miyajima,Nobuyuki Hyakuna et al.
Hisashi Ishida et al.
Background: Philadelphia-negative (Ph-negative) myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), are exceptionally rare during childho...
RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation [0.03%]
BRAF突变的多发性骨髓瘤患者接受达拉菲尼和曲美替尼治疗产生获得性耐药性的RAS突变机制分析
Baptiste Le Calvez,Yannick Le Bris,Guillaume Herbreteau et al.
Baptiste Le Calvez et al.
Multiple myeloma (MM) is still considered incurable and new therapeutic approaches are therefore needed. Deep-sequencing analysis revealed the presence of BRAF mutations in up to 15% of patients. The clinical experience of BRAF-targeted the...
Case Reports
EJHaem. 2020 Aug 6;1(1):318-322. DOI:10.1002/jha2.8 2020
Favourable outcomes for high-risk Burkitt lymphoma patients (IPI 3-5) treated with rituximab plus CODOX-M/IVAC: Results of a phase 2 UK NCRI trial [0.03%]
利妥昔单抗联合CODOX-M/IVAC方案治疗高危伯基特淋巴瘤（IPI评分3-5分）患者的积极结果：一项II期UK NCRI试验结果
Elizabeth H Phillips,Catherine Burton,Amy A Kirkwood et al.
Elizabeth H Phillips et al.
Introduction: Outcomes after frontline treatment of Burkitt lymphoma (BL) have improved with the introduction of dose-intense chemotherapy regimens, such as CODOX-M/IVAC. While rituximab has increased survival rates for m...
Severe acute intestinal graft versus host disease requiring surgical resection [0.03%]
重症肠道移植物抗宿主病并需要手术治疗
Hisashi Ishida,Takuo Noda,Seiji Kawano et al.
Hisashi Ishida et al.
Case Reports
EJHaem. 2020 Jun 3;1(1):328-329. DOI:10.1002/jha2.24 2020